InGeNA welcomes our new associate member Bespoke Genetic Medicines Inc InGeNA is delighted to welcome our new Associate Member: Bespoke Genetic Medicines Inc. Where Traditional pharmaceutical companies develop one drug for millions of patients, at Bespoke Genetic...
InGeNA welcomes our new partner the Griffith University Institute for Biomedicine and Glycomics InGeNA is delighted to welcome Griffith University’s Institute for Biomedicine and Glycomics as our newest partner. IBG is a multidisciplinary biomedical research institute...
A Nature news feature has profiled a new wave of companies developing a different kind of gene therapy. Rather than cutting DNA, these therapies change the chemical markers that sit on it and switch genes on or off. The approach is called epigenetic editing. The...
A new study in the New England Journal of Medicine reports promising results from a CRISPR gene-editing therapy in children aged 5 to 11. The children had severe sickle cell disease or transfusion-dependent beta thalassaemia, both inherited blood disorders. HCA...
Supporting the translation of genomic results into clinical action InGeNA and HGSA are collaborating on a national project examining the presentation of therapeutic recommendations in somatic oncology next-generation sequencing reports. As precision oncology advances,...
InGeNA is delighted to host Dame Professor Sue Hill, Chief Scientific Officer for England and Senior Responsible Officer for Genomics in the NHS, during her visit to Australia from 12 to 16 October 2026. Dame Professor Sue Hill has played a leading role in...
